Basaglar is a biosimilar insulin product that can be used as a substitute for other long-acting insulins. It is designed to be similar to Lantus, another long-acting insulin.
How does Basaglar work?
Basaglar, like other long-acting insulins, is intended to provide a basal (background) insulin level over a 24-hour period. It helps to control blood sugar levels between meals and overnight. It is a modification of human insulin, designed for prolonged action. [1]
What is the difference between Basaglar and Lantus?
Basaglar (insulin glargine-yf) is a brand name for a biosimilar insulin glargine product. Lantus is the brand name for insulin glargine, the reference product. Biosimilar products are approved based on their high degree of similarity to the reference product in terms of structure, function, and safety, with no clinically meaningful differences. [2]
Can I switch from Lantus to Basaglar?
Patients can switch from Lantus to Basaglar. The decision to switch and the management of diabetes should be made in consultation with a healthcare professional. [2]
When does Basaglar's patent expire?
The patent landscape for biosimilar insulin glargine products like Basaglar is complex, involving patents on the original reference product (Lantus) and any new patents filed for the biosimilar itself. Specific patent expiry dates can be found on specialized databases, such as DrugPatentWatch.com. [3]